IV Tubing Sets And Accessories Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global IV Tubing Sets And Accessories Market Trends and Insights

Rapid Growth in Home-Infusion Therapies

Home infusion has shifted the IV tubing sets & accessories market by moving demand from short hospital stays to prolonged outpatient use. Payers now reimburse parenteral nutrition and chemotherapy administered at home, which requires tubing with higher durability and user-friendly connectors. The FDA has released guidance emphasizing closed pathways and needle-free valves to prevent contamination in settings without continuous clinical supervision. Smart pumps paired with RFID-tagged tubing allow remote monitoring, so caregivers receive alerts when flow deviates from prescribed parameters. As providers adopt these systems, manufacturers that bundle consumables with cloud-connected pumps secure sticky revenue streams. The shift also reduces inpatient costs, a point that aligns with health system strategies focused on lowering readmission penalties.

Shift Toward Needle-Free Closed IV Systems

Needle-free connectors reduce occupational exposure and cut the number of breach points that can harbor pathogens. California’s AB 2300 law sparked broader adoption by mandating closed systems in acute-care facilities, a template many states and countries now emulate ^{[2]California Legislative Information, “Assembly Bill No. 2300,” leginfo.legislature.ca.gov} . Clinical studies show decreased catheter-related bloodstream infections when connectors incorporate mechanical valves that stay closed unless positively displaced. Market leaders respond with antimicrobial coatings and color-change indicators that confirm proper disinfection. Training remains essential because poor scrubbing technique negates device benefits. Early adopters in the United States influence purchasing behavior in Asia-Pacific, where hospitals upgrading to Joint Commission International standards must include closed-system components.

Rising Surgical Volumes in Emerging Economies

Infrastructure projects across China, India, and Southeast Asia add operating suites that require full IV ecosystems. Governments invest in universal coverage, and growing middle-class populations opt for elective procedures. These markets favor cost-effective primary sets but quickly shift to secondary sets as case complexity rises. Complex cardiac and oncologic surgeries demand multi-lumen central lines, stimulating the IV tubing sets & accessories market, especially premium accessories such as pressure transducers. Manufacturers entering these markets localize supply to avoid tariffs and meet certification timelines, locking in volume contracts with public procurement agencies ^{[3]Asian Development Bank, “Health Care Financing in Asia and the Pacific,” adb.org}.

Government Initiatives Improving Vascular-Access Safety

WHO guidelines published in 2025 call for closed infusion pathways, connector disinfection protocols, and staff certification programs. Public hospitals that implement these standards influence private facilities via shared labor pools and reference pricing. Procurement specifications now list compatibility with needle-free valves as a mandatory requirement, which narrows the vendor list and elevates compliance as a competitive differentiator. Manufacturers that fund clinician education enjoy preferred-supplier status because training aligns with value-based purchasing goals that tie reimbursement to infection metrics.

Stringent Regulatory Framework

The FDA and European MDR both demand real-world evidence before approving new tubing materials, lengthening development cycles and raising compliance costs. Notified-body bottlenecks in Europe delay market entry for smaller innovators. Cybersecurity clauses extend to any tubing that communicates with connected pumps, adding penetration testing and documentation steps unheard of a decade ago. While these rules favor entrenched firms with dedicated regulatory teams, they also slow innovation in niche segments such as pediatric oncology where specialized tubing could lower error rates. Start-ups often partner with established OEMs to piggyback on existing quality systems, but profit sharing erodes their margins.

Plasticizer and PVC-Phthalate Bans

Legislation in several U.S. states and the European Union restricts di-ethylhexyl phthalate (DEHP) use in devices that contact fluids for extended periods. Manufacturers must reformulate PVC blends or switch to alternative polymers like TPU. Reformulation drives up raw-material costs and necessitates new biocompatibility testing. Hospitals, though concerned about endocrine disruption, resist price hikes without demonstrated clinical benefit. Long-term, the bans encourage innovations in bio-based plastics, yet supply remains limited, so transition adds volatility to the IV tubing sets & accessories market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Secondary Sets Ignite Growth Amid Primary Set Dominance

Primary IV tubing sets accounted for 45.12% of revenue in 2025, underpinning the procedural backbone of routine hydration and antibiotic administration across all care settings. Their high installed base and standardized connectors keep them indispensable, anchoring bulk-purchase contracts that underpin the IV tubing sets & accessories industry. Yet the same contracts increasingly bundle secondary tubing, a category forecast to grow at 6.11% CAGR as clinicians adopt multi-drug regimens that call for parallel infusions without pausing the primary line. This rise dovetails with smart pumps that auto-adjust flow through each lumen, ensuring precise dosing even in home settings. Manufacturers add value by integrating anti-siphon valves and back-check features, enhancing safety while justifying moderate price premiums.

Extension sets and accessory portfolios expand as providers seek ergonomic options that reduce line restarts when repositioning patients. Demand intensifies in critical-care units where equipment density requires flexible routing solutions. Blood administration sets and chemotherapy-grade lines fall under the Others category, where chemical compatibility and light-blocking materials command premium prices. RFID tagging within select tubing ranges allows the pump to authenticate each set, reducing misload events. As digital traceability becomes routine, proprietary connectors strengthen lock-in effects, influencing the IV tubing sets & accessories market size tied to replacement cycles.

By Application: Central Access Surges as Therapies Grow Complex

Peripheral catheter insertion maintained 40.95% share in 2025, reflecting its ubiquity and nurse-driven placement at bedside. Short-term antibiotics and hydration keep demand steady. However, central venous catheter placement is rising swiftly, predicted to outpace peripheral growth and register a 6.18% CAGR. Oncologic and critical-care protocols that rely on high-osmolar infusates prefer central access to prevent vessel damage, which in turn pulls through multi-lumen compatible tubing. The IV tubing sets & accessories market share benefits when hospitals replace one-size-fits-all kits with procedure-specific bundles that reduce setup time.

PICC line insertion bridges the gap between short and chronic therapy, gaining ground as ultrasound guidance improves success rates. Specialty sets with minimal priming volume and anti-reflux valves lower infection risk, broadening outpatient usage. The Others segment encompasses arterial lines and neonatal applications where pressure tolerance and micro-bore dimensions are critical. Advances in polyurethane formulations that combine flexibility with high tensile strength help minimize thrombosis, encouraging adoption in long-dwell scenarios. Emerging evidence from neonatal intensive care units highlights reduced complication rates when tubing materials match catheter chemistry, driving cross-selling opportunities for integrated vendors.

By End User: Ambulatory Centers Outpace Hospital Giants

Hospitals remained the primary consumer, gripping 70.55% of the IV tubing sets & accessories market size in 2025 due to their broad procedure mix and need for high inventory turnover. Central supply departments favor bulk packaging and standardized connectors that simplify logistics across intensive care, oncology, and surgery. Yet ambulatory surgical centers (ASCs) are rapidly narrowing the gap with a 6.32% forecast CAGR. ASCs rely on rapid room turnover and minimal staffing ratios, so they invest in tubing that combines quick-connect ports with visual anti-free-flow indicators, cutting setup time per case. Bundled infusion kits tailored to common outpatient procedures, such as orthopedic arthroscopy, align with reimbursement models that penalize delays.

Home-care settings, although still a smaller slice, post consistent growth as aging populations opt for therapy at home. Portable elastomeric pumps paired with low-weight, kink-resistant tubing extend dwell times and reduce emergency department visits, reinforcing payer support. The Others segment includes dialysis centers and long-term care facilities where infection-control standards mirror hospital requirements yet budget constraints drive preference for cost-optimized, high-volume tubing. Value-based care contracts incentivize providers to select systems with proven durability, helping reduce line replacement costs over the episode of care.

Geography Analysis

North America held 41.55% of global revenue in 2025, strengthened by early adoption of closed-system connectors, stringent OSHA mandates, and bundled multi-product contracts that include pumps, solutions, and disposables. Hurricanes and pandemic-related freight disruptions exposed supply chain weaknesses, prompting U.S. manufacturers to invest almost USD 1 billion in domestic capacity that cushions against future shocks. Regional payers now reimburse infection-prevention add-ons, which encourages hospitals to pay a premium for antimicrobial ports and RFID-enabled sets.

Asia-Pacific posts the fastest regional CAGR at 6.27% through 2031, fueled by rising surgical caseloads and expansion of public insurance schemes in China and India. Volume-based procurement models encourage bulk orders of standardized tubing, yet regulators simultaneously tighten safety criteria, creating a two-tier market. Local firms win spot tenders on price, whereas multinational brands capture tertiary hospitals that prioritize infection metrics for medical tourism. APAC governments also channel grants into smart-pump pilots, driving accompanying demand for compatible tubing coded with GS1 identifiers.

Europe occupies the second-largest share, anchored by evidence-based procurement guidelines that stress clinical data over headline price. The post-Brexit regulatory split raised compliance costs, compelling manufacturers to maintain parallel EU and UK submissions. Germany and France continue to favor premium closed systems, while Eastern European hospitals climb the maturity curve. Middle East and Africa register early-stage adoption, yet Gulf Cooperation Council investments in flagship medical cities generate pockets of high-value demand. South America’s growth is steadier; Brazil’s economic rebound and Argentina’s currency stabilization unlock new device purchases, though import duties influence price positioning.

Regulatory Landscape

IV tubing sets and accessories are regulated as medical devices in major markets, which shapes design controls, testing, and documentation requirements. In the United States, intravascular administration sets fall under FDA Class II (21 CFR 880.5440) with 510(k) clearance requirements, and review-cycle planning is material for product refreshes, with 510(k) review times for the relevant device grouping cited at about 184 days in recent periods. The FDA Quality Management System Regulation (QMSR) final rule issued in February 2024 tightens lifecycle control and supplier management, incorporating ISO 13485:2016 by reference and increasing the compliance burden for manufacturers and critical component suppliers.

In Europe, IV tubing sets and accessories are governed under the EU Medical Device Regulation (MDR 2017/745), where accessories are assessed within the same framework as the parent device and must demonstrate conformity to General Safety and Performance Requirements (GSPR), with post-market surveillance readiness. Notified body expectations for technical documentation continue to evolve, including Team-NB guidance updates published in April 2026 that influence how manufacturers assemble evidence packages for review. Across regions, adherence to international consensus standards remains central for market access and tender eligibility, including ISO 8536-4:2019 for single-use gravity-feed infusion sets. In 2025, Korea aligned national requirements through KS P ISO 8536-4-2025, reinforcing cross-border standardization for manufacturers supplying Asia-Pacific procurement programs.

Value Chain Analysis

The value chain for IV tubing sets and accessories runs from medical-grade polymer and additive suppliers (PVC and non-PVC formulations, plasticizers, and colorants) through component and toolmakers (molding, extrusion, filters, clamps, connectors, needle-free valves, and luer interfaces), and then to device manufacturers and contract manufacturers covering assembly, packaging, sterilization, and labeling. Downstream channels include distributors, group purchasing organizations (GPOs), and providers such as hospitals, ambulatory surgical centers, and home-infusion providers. Quality and regulatory controls sit across the chain, from incoming resin qualification and process validation through sterilization lot release and traceability, with compliance increasingly aligned to ISO 13485-based requirements following the FDA QMSR final rule in February 2024.

Large OEMs often rely on bundled agreements that link pumps, software, and proprietary consumables to stabilize demand and improve forecast accuracy, while distributors and GPOs push for standardization and availability in response to high-volume, recurring consumption patterns. Operational risk clusters around resin availability, sterilization capacity, and logistics continuity, and external shocks can cascade into shortages and substitution behavior. The late-2024 IV fluid disruption after hurricane damage highlighted concentrated manufacturing footprints and just-in-time inventory exposure, prompting providers to ration usage and reduce elective procedures, which then affected adjacent consumables planning and allocation. Industry bodies and networks supporting supply visibility and policy advocacy, including AdvaMed, MDMA, AIMED, and the Medical Device Supply Chain Council, have reinforced initiatives around end-to-end transparency, dual sourcing, and domestic capacity resilience. As material restrictions on DEHP and PVC expand, upstream reformulation and revalidation add cost and lead time, which increases the strategic value of qualified alternative polymers and vertically integrated manufacturing that can shorten investigation cycles during quality events and recalls.

Market Opportunities and Future Outlook

A key opportunity is aligning tubing sets and accessories with infection-prevention and closed-system purchasing mandates across hospitals, ambulatory sites, and home infusion. In these settings, compatibility with needle-free connectors and traceability features is increasingly reflected in procurement specifications. WHO bloodstream-infection prevention guidance updated in February 2025 reinforced closed infusion pathways and connector disinfection protocols, supporting demand for integrated systems that reduce contamination risk and standardize bedside workflows.

Another visible whitespace involves conversion away from DEHP-containing materials, driven by state-level restrictions and broader PVC-phthalate scrutiny. This is accelerating qualification of alternative polymers and sharpening supplier selection toward vendors with validated non-DEHP portfolios and testing capabilities aligned to ISO 8536-4. Supply resilience and regional manufacturing footprints also shape near-term investment and sourcing decisions. In North America, several large-scale actions indicate that providers and manufacturers are prioritizing domestic availability after the 2024 shortage environment: B. Braun reported adding capacity of more than 30 million IV sets annually (October 2024), BD announced USD 30 million of planned 2025 investments to expand IV line manufacturing at its Utah plant, and Otsuka ICU Medical announced in July 2026 a USD 500 million investment to build a new 500,000-square-foot facility and upgrade an existing 700,000-square-foot site in Austin, Texas, supporting non-DEHP IV solutions manufacturing. These expansions create room for tubing and accessory suppliers that can qualify into expanded lines, meet tighter quality-system requirements, and support large IDN and GPO contracts with dual-sourced, traceable, and closed-system compatible product families.